New drug aims to cut bleeds in half for hemophilia patients
NCT ID NCT07416526
First seen Feb 28, 2026 · Last updated May 16, 2026 · Updated 6 times
Summary
This study tests a new medicine called NXT007 to see if it works better than the standard factor VIII treatment at preventing bleeding episodes in people with hemophilia A who do not have inhibitors. About 126 participants aged 12 and older with severe or moderate hemophilia A will receive either NXT007 or factor VIII and be monitored for bleeds over the treatment period. The goal is to find a more effective way to control the disease and reduce the number of bleeds.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMOPHILIA A are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Nara Medical University Hospital
RECRUITINGKashihara-shi, Nara, 634-8522, Japan
-
Tokyo Medical University Hospital
RECRUITINGShinjuku-Ku, Tokyo, 160-0023, Japan
Conditions
Explore the condition pages connected to this study.